Literature DB >> 27600094

Stem cell markers in glioma progression and recurrence.

Kirsten Hattermann1, Charlotte Flüh2, Dorothee Engel1, H Maximilian Mehdorn2, Michael Synowitz2, Rolf Mentlein1, Janka Held-Feindt2.   

Abstract

Aggressive cancer cells show histological similarities to embryonic stem cells. As differentiated cells can re-acquire pluripotency and self-renewal by transfection with the transcription factors OCT4, SOX2, KLF4 and MYC, with Nanog as readout for success, we comprehensively investigated their occurrence and frequency in human astrocytomas of different malignancy grades, primary and matched recurrent glioblastomas, short- and long-term glioblastoma cultures and glioma cell lines. Among astrocytomas, mRNA expression of OCT4, MYC and (less robust) KLF4 increased with malignancy, while in recurrent glioblastomas MYC expression slightly decreased. Correlation analysis revealed distinct positive correlation between distinct stem cell markers, and this effect was most prominent in the recurrent glioblastoma cohort. In situ, embryonic stem cell factors were found also in more differentiated tumor regions. Respective cells were rarely actively proliferating and showed single or combined expression signatures, which, at least in parts, corresponded to observed positive correlations of mRNA expression. However, a 'master-marker' defining the complete glioma stem cell subset could not be confirmed. In glioma cell lines, long- and short-term cultures, embryonic markers were detected at comparable levels. Upon exposure to temozolomide, increased expression of KLF4 (and lesser Nanog and OCT4) was observed. Experimental intrinsic overexpression of SOX2, KLF4 or OCT4 did not affect the other stem cell factors. The embryonic stem cell factors comprehensively investigated in this project can control self-renewal and pluripotency, and therefore tumorigenicity. They should be considered for the development of future diagnostic and therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27600094     DOI: 10.3892/ijo.2016.3682

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  27 in total

1.  Cationic lipoplexes for treatment of cancer stem cell-derived murine lung tumors.

Authors:  Terrick Andey; Namrata Bora-Singhal; Srikumar P Chellappan; Mandip Singh
Journal:  Nanomedicine       Date:  2019-03-01       Impact factor: 5.307

2.  MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.

Authors:  Chiung-Yuan Ko; Chao-Han Lin; Jian-Ying Chuang; Wen-Chang Chang; Tsung-I Hsu
Journal:  Mol Neurobiol       Date:  2017-05-06       Impact factor: 5.590

3.  NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.

Authors:  Charlotte Flüh; Guranda Chitadze; Vivian Adamski; Kirsten Hattermann; Michael Synowitz; Dieter Kabelitz; Janka Held-Feindt
Journal:  Histochem Cell Biol       Date:  2018-01-22       Impact factor: 4.304

Review 4.  Cancer and stem cells.

Authors:  Wen Yin; Jialing Wang; Linling Jiang; Y James Kang
Journal:  Exp Biol Med (Maywood)       Date:  2021-04-05

5.  Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment.

Authors:  Kirsten Hattermann; Janka Held-Feindt; Vivian Adamski; Annika Hempelmann; Charlotte Flüh; Ralph Lucius; Michael Synowitz
Journal:  Oncotarget       Date:  2017-11-18

6.  Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.

Authors:  Fengyu Zhang; Ruilai Liu; Haishi Zhang; Cheng Liu; Chunfang Liu; Yuan Lu
Journal:  BMC Cancer       Date:  2020-07-18       Impact factor: 4.430

7.  Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme.

Authors:  Ramcharan Singh Angom; Sujan Kumar Mondal; Fei Wang; Vijay Sagar Madamsetty; Enfeng Wang; Shamit K Dutta; Yash Gulani; Rachel Sarabia-Estrada; Jann N Sarkaria; Alfredo Quiñones-Hinojosa; Debabrata Mukhopadhyay
Journal:  Oncogene       Date:  2020-10-01       Impact factor: 9.867

Review 8.  In Vitro Glioblastoma Models: A Journey into the Third Dimension.

Authors:  Mayra Paolillo; Sergio Comincini; Sergio Schinelli
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

9.  Modeling treatment-dependent glioma growth including a dormant tumor cell subpopulation.

Authors:  Marvin A Böttcher; Janka Held-Feindt; Michael Synowitz; Ralph Lucius; Arne Traulsen; Kirsten Hattermann
Journal:  BMC Cancer       Date:  2018-04-03       Impact factor: 4.430

10.  MicroRNA-136-3p inhibits glioma tumorigenesis in vitro and in vivo by targeting KLF7.

Authors:  Yanwu Xu
Journal:  World J Surg Oncol       Date:  2020-07-16       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.